Literature DB >> 32563557

TLR2 as a Therapeutic Target in Bacterial Infection.

Morgan E Simpson1, William A Petri2.   

Abstract

Toll-like receptor (TLR) 2 recognizes and responds to threats early in bacterial infections and can influence the downstream immune response to the host's benefit or detriment. Therapeutic modulation of TLR2 signaling represents an underutilized opportunity to moderate the immune response to infection to promote an improved outcome for the host.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  TLR2; bacterial infection; immunotherapy; innate immunity

Mesh：

Substances：

Year:  2020        PMID： 32563557      PMCID： PMC7845793          DOI： 10.1016/j.molmed.2020.05.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  10 in total

1.  Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells.

Authors:  Aideen C Allen; Mieszko M Wilk; Alicja Misiak; Lisa Borkner; Dearbhla Murphy; Kingston H G Mills
Journal:  Mucosal Immunol       Date:  2018-08-20       Impact factor: 7.313

2.  Decoy peptides derived from the extracellular domain of toll-like receptor 2 (TLR2) show anti-inflammatory properties.

Authors:  S Ebner; M Trieb; M Schönfeld; G Wietzorrek; S Santos-Sierra
Journal:  Bioorg Med Chem       Date:  2018-07-09       Impact factor: 3.641

3.  Mycobacterium tuberculosis PPE18 Protein Reduces Inflammation and Increases Survival in Animal Model of Sepsis.

Authors:  Asma Ahmed; Komal Dolasia; Sangita Mukhopadhyay
Journal:  J Immunol       Date:  2018-04-18       Impact factor: 5.422

4.  Suppression of Th1 Priming by TLR2 Agonists during Cutaneous Immunization Is Mediated by Recruited CCR2+ Monocytes.

Authors:  Christopher T Johndrow; Michael F Goldberg; Alison J Johnson; Tony W Ng; Shajo Kunnath-Velayudhan; Gregoire Lauvau; Daniel H Kaplan; Graeme H Gossel; Ulrich D Kadolsky; Andrew J Yates; John Chan; William R Jacobs; Steven A Porcelli
Journal:  J Immunol       Date:  2018-11-19       Impact factor: 5.422

5.  TLR2 engagement on CD4(+) T cells enhances effector functions and protective responses to Mycobacterium tuberculosis.

Authors:  Scott M Reba; Qing Li; Sophia Onwuzulike; Xuedong Ding; Ahmad F Karim; Yeritza Hernandez; Scott A Fulton; Clifford V Harding; Christina L Lancioni; Nancy Nagy; Myriam E Rodriguez; Pamela A Wearsch; Roxana E Rojas
Journal:  Eur J Immunol       Date:  2014-03-14       Impact factor: 5.532

6.  Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids.

Authors:  Landry Blanc; Martine Gilleron; Jacques Prandi; Ok-Ryul Song; Mi-Seon Jang; Brigitte Gicquel; Daniel Drocourt; Olivier Neyrolles; Priscille Brodin; Gérard Tiraby; Alain Vercellone; Jérôme Nigou
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-02       Impact factor: 11.205

7.  Meningococcal PorB induces a robust and diverse antigen specific T cell response as a vaccine adjuvant.

Authors:  Munir Mosaheb; Lee M Wetzler
Journal:  Vaccine       Date:  2018-10-28       Impact factor: 3.641

8.  Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis.

Authors:  Cristiano Xavier Lima; Danielle Gloria Souza; Flavio Almeida Amaral; Caio Tavares Fagundes; Irla Paula Stopa Rodrigues; Jose Carlos Alves-Filho; Marie Kosco-Vilbois; Walter Ferlin; Limin Shang; Greg Elson; Mauro Martins Teixeira
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

9.  Control of Methicillin-Resistant Staphylococcus aureus Pneumonia Utilizing TLR2 Agonist Pam3CSK4.

Authors:  Yi-Guo Chen; Yong Zhang; Lin-Qiang Deng; Hui Chen; Yu-Juan Zhang; Nan-Jin Zhou; Keng Yuan; Li-Zhi Yu; Zhang-Hua Xiong; Xiao-Mei Gui; Yan-Rong Yu; Xiao-Mu Wu; Wei-Ping Min
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

10.  The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia.

Authors:  Carrie A Cowardin; Erica L Buonomo; Mahmoud M Saleh; Madeline G Wilson; Stacey L Burgess; Sarah A Kuehne; Carsten Schwan; Anna M Eichhoff; Friedrich Koch-Nolte; Dena Lyras; Klaus Aktories; Nigel P Minton; William A Petri
Journal:  Nat Microbiol       Date:  2016-07-11       Impact factor: 17.745
  10 in total
  5 in total

Review 1.  Bacterial Translocation in Gastrointestinal Cancers and Cancer Treatment.

Authors:  Keita Kouzu; Hironori Tsujimoto; Yoji Kishi; Hideki Ueno; Nariyoshi Shinomiya
Journal:  Biomedicines       Date:  2022-02-04

Review 2.  The Role of TLR2 in Infectious Diseases Caused by Mycobacteria: From Cell Biology to Therapeutic Target.

Authors:  Wanbin Hu; Herman P Spaink
Journal:  Biology (Basel)       Date:  2022-02-05

Review 3.  Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications.

Authors:  Chung-Nga Ko; Shaohong Zang; Yingtang Zhou; Zhangfeng Zhong; Chao Yang
Journal:  J Nanobiotechnology       Date:  2022-08-19       Impact factor: 9.429

4.  Rhodococcus equi-Derived Extracellular Vesicles Promoting Inflammatory Response in Macrophage through TLR2-NF-κB/MAPK Pathways.

Authors:  Zhaokun Xu; Xiujing Hao; Min Li; Haixia Luo
Journal:  Int J Mol Sci       Date:  2022-08-28       Impact factor: 6.208

5.  Shifting focus from bacteria to host neutrophil extracellular traps of biodegradable pure Zn to combat implant centered infection.

Authors:  Feng Peng; Juning Xie; Haiming Liu; Yufeng Zheng; Xin Qian; Ruixiang Zhou; Hua Zhong; Yu Zhang; Mei Li
Journal:  Bioact Mater       Date:  2022-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.